clonidine has been researched along with Dementia Praecox in 50 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind placebo-controlled randomized clinical trial, 32 chronic schizophrenia patients were randomly assigned to six-weeks augmentation with either 50 μg clonidine or placebo to their current medication." | 9.69 | Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial. ( Bakker, PR; Durston, S; Koster, M; Kruiper, C; Oranje, B; Sommer, IEC, 2023) |
| "In a double-blind, placebo-controlled, randomized yet balanced cross-over design, 20 male schizophrenia patients on stable medication were assessed in a psychophysiological test battery, including a sensory gating paradigm on 5 occasions: once after oral administration of placebo and after single doses of 25, 50, 75, and 150 µg of clonidine." | 9.19 | Clonidine normalizes levels of P50 gating in patients with schizophrenia on stable medication. ( Glenthøj, BY; Oranje, B, 2014) |
| "In a double blind, placebo controlled, randomized, yet balanced, cross-over experiment, 20 male schizophrenia patients on stable medication were assessed in an auditory prepulse inhibition (PPI), sensitization, and habituation of the startle reflex paradigm on 5 occasions: once after oral administration of placebo and after a single dose of 25, 50, 75, and 150 µg of clonidine." | 9.17 | Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication. ( Glenthøj, BY; Oranje, B, 2013) |
| "Clozapine has shown superior efficacy in treatment of refractory schizophrenia, but its use is limited by emergent side-effects." | 9.11 | Is clonidine useful for treatment of clozapine-induced sialorrhea? ( Praharaj, SK; Roy, D; Singh, A; Verma, P, 2005) |
| "The role of alpha 2-adrenergic receptor sensitivity in schizophrenia was examined by measuring growth hormone (GH) response after the intravenous administration of clonidine (1." | 7.68 | Growth hormone response to clonidine in neuroleptic-free patients with multidagnostically defined schizophrenia. ( Copolov, DL; Hassett, A; Hill, C; Hirt, J; Keks, NA; Kulkarni, J; Mackie, B; Matheson, B; McKenzie, DP; Singh, B, 1993) |
| " The hypothesis that the functional sensitivity of this presynaptic regulation of NE is impaired in schizophrenia was tested by evaluating, in schizophrenic patients and age-matched normal controls, the ability of clonidine, an alpha 2 agonist, to lower plasma levels of the NE metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) and to lower blood pressure (BP)." | 7.66 | Impaired presynaptic regulation of norepinephrine in schizophrenia. Effects of clonidine in schizophrenic patients and normal controls. ( Charney, DS; Hafstad, KM; Heninger, GR; Landis, DH; Leckman, JF; Sternberg, DE, 1982) |
| "Clonidine was selected because it blocks noradrenergic but not dopaminergic neurotransmission." | 6.65 | Clonidine treatment of schizophrenia. Double-blind comparison to placebo and neuroleptic drugs. ( Adler, LE; Bell, J; Denver, P; Freedman, R; Kirch, D; Pachtman, E; Pecevich, M, 1982) |
| "In a double-blind placebo-controlled randomized clinical trial, 32 chronic schizophrenia patients were randomly assigned to six-weeks augmentation with either 50 μg clonidine or placebo to their current medication." | 5.69 | Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial. ( Bakker, PR; Durston, S; Koster, M; Kruiper, C; Oranje, B; Sommer, IEC, 2023) |
| "In a double-blind, placebo-controlled, randomized yet balanced cross-over design, 20 male schizophrenia patients on stable medication were assessed in a psychophysiological test battery, including a sensory gating paradigm on 5 occasions: once after oral administration of placebo and after single doses of 25, 50, 75, and 150 µg of clonidine." | 5.19 | Clonidine normalizes levels of P50 gating in patients with schizophrenia on stable medication. ( Glenthøj, BY; Oranje, B, 2014) |
| "In a double blind, placebo controlled, randomized, yet balanced, cross-over experiment, 20 male schizophrenia patients on stable medication were assessed in an auditory prepulse inhibition (PPI), sensitization, and habituation of the startle reflex paradigm on 5 occasions: once after oral administration of placebo and after a single dose of 25, 50, 75, and 150 µg of clonidine." | 5.17 | Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication. ( Glenthøj, BY; Oranje, B, 2013) |
| "Clozapine has shown superior efficacy in treatment of refractory schizophrenia, but its use is limited by emergent side-effects." | 5.11 | Is clonidine useful for treatment of clozapine-induced sialorrhea? ( Praharaj, SK; Roy, D; Singh, A; Verma, P, 2005) |
| "Clonidine's actions and efficacy in mental disorders are reviewed and examined." | 5.06 | Psychiatric indications for clonidine: the neuropharmacologic and clinical basis. ( Bond, WS, 1986) |
| " Among the more important recent discoveries are the efficacy of the tricyclic antidepressants for panic disorder and agoraphobia with panic attacks; the use of the monoamine oxidase inhibitors for the above disorders and for atypical depression and hysteroid dysphoria; the use of propranolol for anxiety disorders and for uncontrollable violent outbursts; the antianxiety and antipanic effects of clonidine; and the usefulness of lithium in treating schizophrenia and schizoaffective disorder and for emotionally unstable character disorders." | 4.76 | Newer uses for older psychotropic medications. ( Liebowitz, MR, 1982) |
| " A human study using patients with schizophrenia demonstrated an exacerbation of polydipsia by the administration of clonidine, an ADRA2A-agonist, and a relief of polydipsia by mianserin, an ADRA2A-antagonist, suggesting the involvement of the central adrenergic system in the drinking behavior of patients with schizophrenia." | 3.75 | Association analysis between the C-1291G polymorphism in the promoter region of the adrenergic alpha2A receptor gene and polydipsia in schizophrenia. ( Chen, HI; Fukunaka, Y; Hwang, R; Inoue, Y; Nakamura, J; Ohmori, O; Sakata, S; Shinkai, T; Utsunomiya, K; Yamada, K; Yamaguchi, W, 2009) |
| "The binding of [125I]p-iodoclonidine to alpha-2, and/or [125I]iodopindolol to beta-1 and beta-2 adrenoceptors was measured in right prefrontal cortex (Brodmann's area 10) and right hippocampus from subjects with DSM-III-R diagnoses of major depression (n = 15) or schizophrenia (n = 8) as well as from control subjects (n = 20)." | 3.70 | Brain noradrenergic receptors in major depression and schizophrenia. ( Dilley, G; Klimek, V; Luker, SN; Meltzer, HY; Ordway, GA; Overholser, JC; Rajkowska, G; Stockmeier, CA, 1999) |
| "The role of alpha 2-adrenergic receptor sensitivity in schizophrenia was examined by measuring growth hormone (GH) response after the intravenous administration of clonidine (1." | 3.68 | Growth hormone response to clonidine in neuroleptic-free patients with multidagnostically defined schizophrenia. ( Copolov, DL; Hassett, A; Hill, C; Hirt, J; Keks, NA; Kulkarni, J; Mackie, B; Matheson, B; McKenzie, DP; Singh, B, 1993) |
| "To investigate the potential effect of Nicergoline, an alpha-adrenolytic drug, on negative symptoms in patients suffering from chronic schizophrenia, we administered this compound to 20 male chronic schizophrenics." | 3.67 | Clinical and biochemical effects of nicergoline in chronic schizophrenic patients. ( Ackenheil, M; Albus, M; Botschev, C; Müller-Spahn, F; Münch, U; Naber, D, 1986) |
| "Three cases of tardive dyskinesia with psychotic symptoms (one presenile psychosis; two schizophrenia) were successfully treated with both clonidine and neuroleptics for 3 years." | 3.66 | Combined treatment of tardive dyskinesia with clonidine and neuroleptics: a follow-up study of three cases for three years. ( Koga, I; Nishikawa, T; Tanaka, M; Uchida, Y, 1983) |
| " The hypothesis that the functional sensitivity of this presynaptic regulation of NE is impaired in schizophrenia was tested by evaluating, in schizophrenic patients and age-matched normal controls, the ability of clonidine, an alpha 2 agonist, to lower plasma levels of the NE metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) and to lower blood pressure (BP)." | 3.66 | Impaired presynaptic regulation of norepinephrine in schizophrenia. Effects of clonidine in schizophrenic patients and normal controls. ( Charney, DS; Hafstad, KM; Heninger, GR; Landis, DH; Leckman, JF; Sternberg, DE, 1982) |
| "Clonidine was administered to twelve chronic schizophrenic patients with TDS in a double-blind, cross-over, single-dose trial." | 2.66 | Clonidine trial in tardive dyskinesia. Therapeutic response, MHPG, and plasma DBH. ( Markianos, M; Tripodianakis, J, 1986) |
| "Clonidine was selected because it blocks noradrenergic but not dopaminergic neurotransmission." | 2.65 | Clonidine treatment of schizophrenia. Double-blind comparison to placebo and neuroleptic drugs. ( Adler, LE; Bell, J; Denver, P; Freedman, R; Kirch, D; Pachtman, E; Pecevich, M, 1982) |
| "Patients with Korsakoff's disease, attention deficit disorder or schizophrenia may benefit from treatment with alpha 2-agents." | 2.39 | Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition. ( Coull, JT, 1994) |
| "Guanfacine, which is an alpha-2 agonist with a higher affinity for the 2A, compared with 2B or 2C, subtypes, also blocked the ability of PCP to increase dopamine efflux in the prefrontal cortex." | 1.35 | Clonidine and guanfacine attenuate phencyclidine-induced dopamine overflow in rat prefrontal cortex: mediating influence of the alpha-2A adrenoceptor subtype. ( Elsworth, JD; Jentsch, JD; Roth, RH; Sanchez, D, 2008) |
| "Treatment with chlorpromazine (CPZ) for 2 weeks further decreased the Bmax for both ligands." | 1.27 | Platelet alpha 2-adrenergic receptors in schizophrenic patients before and after phenothiazine treatment. ( Rice, HE; Rosen, J; Silk, KR; Smith, CB, 1984) |
| " Neuroleptic medications are still the mainstay of treatment, but recent studies suggest new approaches to dosage and to the treatment of acute psychosis." | 1.27 | The pharmacologic treatment of schizophrenia: a progress report. ( Baldessarini, RJ; Donaldson, SR; Gelenberg, AJ, 1983) |
| "Six patients with akathisia were treated with clonidine in an open, on-drug/off-drug trial." | 1.27 | Use of clonidine in treating neuroleptic-induced akathisia. ( Cohen, BM; Jonas, JM; Lipinski, JF; Zubenko, GS, 1984) |
| "Our findings suggest that patients with endogenous depression are characterized by a subsensitivity of postsynaptic alpha-receptors or of structures related to them." | 1.26 | Effect of clonidine on growth hormone release in psychiatric patients and controls. ( Ackenheil, M; Hippius, H; Matussek, N; Müller, F; Schröder, HT; Schultes, H; Wasilewski, B, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (52.00) | 18.7374 |
| 1990's | 12 (24.00) | 18.2507 |
| 2000's | 5 (10.00) | 29.6817 |
| 2010's | 5 (10.00) | 24.3611 |
| 2020's | 2 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kruiper, C | 2 |
| Sommer, IEC | 1 |
| Koster, M | 1 |
| Bakker, PR | 1 |
| Durston, S | 1 |
| Oranje, B | 4 |
| Yadav, S | 1 |
| Takács, A | 1 |
| Pantelis, C | 1 |
| Thomas, N | 1 |
| Niederhofer, H | 1 |
| Glenthøj, BY | 3 |
| Jentsch, JD | 2 |
| Sanchez, D | 1 |
| Elsworth, JD | 2 |
| Roth, RH | 2 |
| Yamaguchi, W | 1 |
| Shinkai, T | 1 |
| Inoue, Y | 1 |
| Utsunomiya, K | 1 |
| Sakata, S | 1 |
| Fukunaka, Y | 1 |
| Yamada, K | 1 |
| Chen, HI | 1 |
| Hwang, R | 1 |
| Ohmori, O | 1 |
| Nakamura, J | 1 |
| Dardennes, RM | 1 |
| Al Anbar, NN | 1 |
| Rouillon, F | 1 |
| Praharaj, SK | 1 |
| Verma, P | 1 |
| Roy, D | 1 |
| Singh, A | 1 |
| Rice, HE | 2 |
| Smith, CB | 2 |
| Silk, KR | 2 |
| Rosen, J | 3 |
| Freedman, R | 2 |
| Bell, J | 2 |
| Kirch, D | 2 |
| Elizur, A | 1 |
| Levy, A | 1 |
| Lahav, M | 1 |
| Blum, I | 1 |
| Liebowitz, MR | 1 |
| Nishikawa, T | 2 |
| Tanaka, M | 1 |
| Koga, I | 2 |
| Uchida, Y | 2 |
| Lal, S | 1 |
| Nair, NP | 1 |
| Thavundayil, JX | 1 |
| Monks, RC | 1 |
| Guyda, H | 1 |
| Adler, LE | 1 |
| Pecevich, M | 1 |
| Pachtman, E | 1 |
| Denver, P | 1 |
| Donaldson, SR | 1 |
| Gelenberg, AJ | 1 |
| Baldessarini, RJ | 1 |
| Johnson, JM | 1 |
| Zubenko, GS | 1 |
| Cohen, BM | 1 |
| Lipinski, JF | 1 |
| Jonas, JM | 1 |
| Matussek, N | 2 |
| Ackenheil, M | 3 |
| Hippius, H | 1 |
| Müller, F | 1 |
| Schröder, HT | 1 |
| Schultes, H | 1 |
| Wasilewski, B | 1 |
| Sternberg, DE | 2 |
| Charney, DS | 1 |
| Heninger, GR | 1 |
| Leckman, JF | 1 |
| Hafstad, KM | 1 |
| Landis, DH | 1 |
| Jimerson, DC | 1 |
| Post, RM | 1 |
| Stoddard, FJ | 1 |
| Gillin, JC | 1 |
| Bunney, WE | 1 |
| Corrigan, FM | 1 |
| MacDonald, S | 1 |
| Reynolds, GP | 1 |
| Campbell, M | 1 |
| Cueva, JE | 1 |
| Brambilla, F | 1 |
| Marini, S | 1 |
| Saito, A | 1 |
| Fassone, G | 1 |
| Picardi, A | 1 |
| Nerozzi, D | 1 |
| Pancheri, P | 1 |
| Coull, JT | 1 |
| Keks, NA | 1 |
| Copolov, DL | 1 |
| McKenzie, DP | 1 |
| Kulkarni, J | 1 |
| Hassett, A | 1 |
| Matheson, B | 1 |
| Hill, C | 1 |
| Mackie, B | 1 |
| Singh, B | 1 |
| Hirt, J | 1 |
| Maas, JW | 1 |
| Miller, AL | 1 |
| Tekell, JL | 1 |
| Funderburg, L | 1 |
| Silva, JA | 1 |
| True, J | 1 |
| Velligan, D | 1 |
| Berman, N | 1 |
| Bowden, CL | 1 |
| Hayashi, T | 1 |
| Horiguchi, J | 1 |
| Yamawaki, S | 1 |
| Taylor, JR | 1 |
| Redmond, DE | 1 |
| Greendyke, RM | 1 |
| Bernhardt, AJ | 1 |
| Tasbas, HE | 1 |
| Lewandowski, KS | 1 |
| Klimek, V | 1 |
| Rajkowska, G | 1 |
| Luker, SN | 1 |
| Dilley, G | 1 |
| Meltzer, HY | 1 |
| Overholser, JC | 1 |
| Stockmeier, CA | 1 |
| Ordway, GA | 1 |
| Mokrani, M | 1 |
| Duval, F | 1 |
| Diep, TS | 1 |
| Bailey, PE | 1 |
| Macher, JP | 1 |
| Delva, NJ | 1 |
| Chang, A | 1 |
| Hawken, ER | 1 |
| Lawson, JS | 1 |
| Owen, JA | 1 |
| Meana, JJ | 1 |
| Barturen, F | 1 |
| García-Sevilla, JA | 1 |
| Llorca, PM | 1 |
| Wolf, MA | 1 |
| van Kammen, DP | 1 |
| Peters, JL | 1 |
| van Kammen, WB | 1 |
| Yao, JK | 1 |
| McAdam, D | 1 |
| Linnoila, M | 1 |
| Pandey, GN | 1 |
| Janicak, PG | 1 |
| Javaid, JI | 1 |
| Davis, JM | 1 |
| Müller-Spahn, F | 2 |
| Albus, M | 2 |
| Botschev, C | 2 |
| Naber, D | 2 |
| Welter, D | 1 |
| Bondy, B | 1 |
| Svensson, TH | 1 |
| Garver, DL | 2 |
| Wålinder, J | 1 |
| Bond, WS | 1 |
| Tripodianakis, J | 1 |
| Markianos, M | 1 |
| Münch, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00004325] | 200 participants | Observational | 1988-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for clonidine and Dementia Praecox
| Article | Year |
|---|---|
Newer uses for older psychotropic medications.
Topics: Adrenergic beta-Antagonists; Agoraphobia; Anxiety Disorders; Bipolar Disorder; Clonidine; Depressive | 1982 |
Psychiatric uses of antiadrenergic and adrenergic blocking drugs.
Topics: Adult; Alcohol Amnestic Disorder; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; | 1984 |
Biologic tests in psychiatry.
Topics: Anxiety Disorders; Apomorphine; Clonidine; Dexamethasone; Dextroamphetamine; Growth Hormone; Humans; | 1984 |
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II.
Topics: Adolescent; Alprazolam; Anticonvulsants; Antipsychotic Agents; Anxiety, Separation; Bipolar Disorder | 1995 |
Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition.
Topics: Aging; Alcohol Amnestic Disorder; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Clo | 1994 |
[Use of certain cardiological drugs in the treatment of schizophrenia: review of the literature].
Topics: Antipsychotic Agents; Calcium Channel Blockers; Clinical Trials as Topic; Clonidine; Humans; Propran | 1991 |
Ethnic differences in reactions to drugs and xenobiotics. Receptor and binding proteins in endogenous psychoses.
Topics: Antipsychotic Agents; Clonidine; Depressive Disorder; Dopamine; Female; Growth Hormone; Humans; Lith | 1986 |
Clonidine in abstinence reactions: basic mechanisms.
Topics: Adrenergic alpha-Agonists; Animals; Anxiety Disorders; Autonomic Nervous System; Central Nervous Sys | 1986 |
Neuroendocrine findings in the schizophrenias.
Topics: Antipsychotic Agents; Apomorphine; Clonidine; Dexamethasone; Gonadotropin-Releasing Hormone; Growth | 1988 |
Neuroendocrine findings in the schizophrenias.
Topics: Apomorphine; Clonidine; Growth Hormone; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Pitu | 1988 |
15 trials available for clonidine and Dementia Praecox
| Article | Year |
|---|---|
Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial.
Topics: Antipsychotic Agents; Clonidine; Double-Blind Method; Drug Therapy, Combination; Humans; Psychiatric | 2023 |
Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Antipsychotic Agents; Auditory Perception; Cerebral Cor | 2019 |
Clonidine normalizes levels of P50 gating in patients with schizophrenia on stable medication.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Clonidine; Cross-Over Studies; Double-Blind Method; Ele | 2014 |
Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication.
Topics: Acoustic Stimulation; Adrenergic alpha-2 Receptor Agonists; Adult; Blinking; Clonidine; Cognition Di | 2013 |
Is clonidine useful for treatment of clozapine-induced sialorrhea?
Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Clonidine; Clozapine; Female; Humans; Male; | 2005 |
Clonidine treatment of schizophrenia. Double-blind comparison to placebo and neuroleptic drugs.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Blood Pressure; Clinical Trials as Topic; Clonidine; | 1982 |
Psychiatric uses of antiadrenergic and adrenergic blocking drugs.
Topics: Adult; Alcohol Amnestic Disorder; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; | 1984 |
Noradrenergic and dopaminergic interrelation in schizophrenia.
Topics: Adolescent; Adult; Apomorphine; Arousal; Chronic Disease; Clonidine; Dopamine; Growth Hormone; Human | 1994 |
Clonidine plus haloperidol in the treatment of schizophrenia/psychosis.
Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Clonidine; Double-Blind Method; Drug Therapy | 1995 |
Involvement of the alpha2-adrenergic system in polydipsia in schizophrenic patients: a pilot study.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Clonidine; Drinking Behavior; Female; Human | 1997 |
Polydipsia in chronic psychiatric patients: therapeutic trials of clonidine and enalapril.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antipsychotic Agents; Chronic Disease; Clonid | 1998 |
Effects of clonidine in schizophrenic patients with primary polydipsia: three single case studies.
Topics: Adrenergic alpha-Agonists; Adult; Analysis of Variance; Chronic Disease; Clonidine; Dose-Response Re | 2002 |
Clonidine treatment of schizophrenia: can we predict treatment response?
Topics: Adult; Clinical Trials as Topic; Clonidine; Growth Hormone; Homovanillic Acid; Humans; Hydroxyindole | 1989 |
Psychiatric indications for clonidine: the neuropharmacologic and clinical basis.
Topics: Animals; Anxiety; Bipolar Disorder; Clinical Trials as Topic; Clonidine; Double-Blind Method; Drug T | 1986 |
Clonidine trial in tardive dyskinesia. Therapeutic response, MHPG, and plasma DBH.
Topics: Adult; Clinical Trials as Topic; Clonidine; Dopamine beta-Hydroxylase; Double-Blind Method; Dyskines | 1986 |
26 other studies available for clonidine and Dementia Praecox
| Article | Year |
|---|---|
Clonidine induced sexual disinhibition in a patient with treatment-resistant schizophrenia: A case report.
Topics: Clonidine; Humans; Problem Behavior; Schizophrenia | 2021 |
Tizanidine is not effective treating EPMS.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Biperiden; Cholinergic Antagonists; Clonidine; Clopenthix | 2018 |
Clonidine and guanfacine attenuate phencyclidine-induced dopamine overflow in rat prefrontal cortex: mediating influence of the alpha-2A adrenoceptor subtype.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agon | 2008 |
Association analysis between the C-1291G polymorphism in the promoter region of the adrenergic alpha2A receptor gene and polydipsia in schizophrenia.
Topics: Adrenergic alpha-Agonists; Adult; Association; Chi-Square Distribution; Clonidine; DNA Mutational An | 2009 |
Successful augmentation of clozapine-resistant treatment of schizophrenia with clonidine.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Humans; Male; Schizophrenia; Treatment Outcome | 2010 |
Platelet alpha 2-adrenergic receptors in schizophrenic patients before and after phenothiazine treatment.
Topics: Adult; Blood Platelets; Chlorpromazine; Chronic Disease; Clonidine; Humans; Kinetics; Male; Norepine | 1984 |
Clonidine therapy for coexisting psychosis and tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Clonidine; Dyskinesia, Drug-Induced; Female; Humans; Male; Schizophreni | 1980 |
Preliminary trial of clonidine treatment in two patients suffering from chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clonidine; Humans; Male; Psychiatric Status Rating Sca | 1980 |
Combined treatment of tardive dyskinesia with clonidine and neuroleptics: a follow-up study of three cases for three years.
Topics: Antipsychotic Agents; Clonidine; Dementia; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Huma | 1983 |
Clonidine-induced growth hormone secretion in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clonidine; Growth Hormone; Humans; Male; Receptors, Ad | 1983 |
The pharmacologic treatment of schizophrenia: a progress report.
Topics: Acute Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Ca | 1983 |
Use of clonidine in treating neuroleptic-induced akathisia.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety Disorders; Bipolar D | 1984 |
Effect of clonidine on growth hormone release in psychiatric patients and controls.
Topics: Adult; Alcohol Drinking; Bipolar Disorder; Clonidine; Depressive Disorder; Female; Growth Hormone; H | 1980 |
Impaired presynaptic regulation of norepinephrine in schizophrenia. Effects of clonidine in schizophrenic patients and normal controls.
Topics: Adult; Blood Pressure; Brain; Clonidine; Dose-Response Relationship, Drug; Female; Humans; Male; Met | 1982 |
Preliminary trial of the noradrenergic agonist clonidine in psychiatric patients.
Topics: Adult; Bipolar Disorder; Blood Pressure; Clonidine; Depression; Dose-Response Relationship, Drug; Do | 1980 |
Clozapine-induced hypersalivation and the alpha 2 adrenoceptor.
Topics: Antipsychotic Agents; Chronic Disease; Clonidine; Clozapine; Dose-Response Relationship, Drug; Drug | 1995 |
Growth hormone response to clonidine in neuroleptic-free patients with multidagnostically defined schizophrenia.
Topics: Adolescent; Adult; Clonidine; Diagnosis, Differential; Female; Growth Hormone; Humans; Male; Middle | 1993 |
Dysregulation of mesoprefrontal dopamine neurons induced by acute and repeated phencyclidine administration in the nonhuman primate: implications for schizophrenia.
Topics: Animals; Clonidine; Dopamine; Frontal Lobe; Functional Laterality; Haplorhini; Humans; Neurons; Nucl | 1998 |
Brain noradrenergic receptors in major depression and schizophrenia.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Affinity Labels; Aged; Autoradiograph | 1999 |
Multihormonal responses to clonidine in patients with affective and psychotic symptoms.
Topics: Adrenocorticotropic Hormone; Adult; Clonidine; Depressive Disorder, Major; Female; Hormones; Human G | 2000 |
Alpha 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Binding, Competitive; Brain; | 1992 |
Increased 3H-clonidine binding in the platelets of patients with depressive and schizophrenic disorders.
Topics: Bipolar Disorder; Blood Platelets; Clonidine; Depressive Disorder; Desipramine; Humans; Imidazoline | 1989 |
Neuroendocrine effects of clonidine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology.
Topics: Adult; Antipsychotic Agents; Clonidine; Clozapine; Growth Hormone; Humans; Hypothalamo-Hypophyseal S | 1986 |
Platelet alpha-2-adrenergic dysfunction in negative symptom schizophrenia: a preliminary study.
Topics: Blood Platelets; Chlorpromazine; Clonidine; Humans; Kinetics; Psychiatric Status Rating Scales; Rece | 1985 |
The use of clonidine in psychiatric disorders. Preliminary clinical observations.
Topics: Anxiety Disorders; Bipolar Disorder; Clonidine; Humans; Mental Disorders; Panic; Psychophysiologic D | 1986 |
Clinical and biochemical effects of nicergoline in chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Clonidine; Epinephrine; Ergolines; Growth Hormone; Humans; Male; Middle Aged | 1986 |